India updates export regulations; AAIPharma continues exec suite turnover;

> India will announce new regulations for pharmaceutical exports to clearly identify product origin and manufacturer in an attempt to "tackle the campaigns on the quality of Indian generics and their wrongful identification with counterfeit drugs." Article

> AAIPharma Services, which last month announced the naming of Patrick Walsh as CEO, has appointed Tim Martin as executive VP for sales and marketing, and Rob Goshert as VP for corporate accounts.  AAIPharma Services release

> Takeda Pharma will build a pharma manufacturing plant in Hikari City, Japan, on the premises of its existing Hikari Plant located in Japan. Story

> Glenn Kazo has been named president at Prolong Pharmaceuticals in South Plainfield, NJ. Prolong release

> Protein production service supplier Laureate Pharma has appointed Steven Johnson to the post of VP for business development. Laureate release

Suggested Articles

Fujifilm Diosynth Biotechnologies last year committed 10 billion yen toward its manufacturing operations. It has now kicked off one of those projects.

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.